Masimo Reports Second Quarter 2013 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Masimo Reports Second Quarter 2013 Financial Results

IRVINE, CA--(Marketwired - Jul 31, 2013) - Masimo ( NASDAQ : MASI ) today announced its financial results for the second quarter ended June 29, 2013.

Q2 2013 Highlights (compared to Q2 2012):

  • Total revenue, including royalties, rose 12% to $137.4 million
  • Product revenue rose 12% to $129.6 million
  • Revenue from rainbow ® products rose 19% to $11.5 million
  • SET ® and rainbow ® SET unit shipments rose 14% to 42,600
  • Net income was $17.0 million, with EPS of $0.30 versus $0.30 in the year-ago period 

Masimo's total second quarter revenue, including royalties, rose 12% to $137.4 million, compared to $122.8 million for the second quarter of 2012. Second quarter 2013 product revenue rose 12% to $129.6 million, compared to $115.3 million for the second quarter of 2012. The company's worldwide direct product revenue grew 10% in the second quarter of 2013 and represented 83% of product revenue. OEM sales, which accounted for 17% of product revenue, rose 27% compared to the same period in 2012. Revenue from sales of Masimo rainbow products rose 19% to $11.5 million in the second quarter, compared to $9.7 million in the year-ago period. Second quarter 2013 rainbow revenue included $3.6 million in sales of total hemoglobin products. 

Net income for the second quarter of 2013 was $17.0 million, or $0.30 per diluted share, compared to net income of $17.7 million, or $0.30 per diluted share, in the second quarter of 2012. 

During the second quarter of 2013, the company shipped approximately 42,600 SET pulse oximetry and rainbow SET Pulse CO-Oximetry units, excluding handheld units, up 14% compared to approximately 37,300 in the same prior-year period. Masimo estimates its worldwide installed base as of June 29, 2013 to be 1,148,000 units, up 11% from 1,033,000 units as of June 30, 2012.

Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, "Our financial performance was strong due to the increase in demand for our breakthrough technologies that have been shown to improve care, reduce cost and increase patient safety. The strong second quarter shipments are indicative of the demand for our innovations."

As of June 29, 2013, Masimo's cash and cash equivalents were $78.1 million, compared to $71.6 million as of December 29, 2012. The change reflects primarily net cash generated from operations, offset by $19.8 million in cash used to repurchase one million shares of Masimo common stock in the first half of 2013. 

Conference Call Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. A live webcast of the conference call will be available online from the investor relations page of the company's corporate website at www.masimo.com . The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 758-3929 for international callers. The reservation code for both dial-in numbers is 19905435. After the live webcast, the call will be available on Masimo's website through August 31, 2013. In addition, a telephonic replay of the call will be available through August 14, 2013. The replay dial-in numbers are (800) 585-8367 for domestic callers and +1 (404) 537-3406 for international callers. Please use reservation code 19905435.

About Masimo Masimo ( NASDAQ : MASI ) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET ® , which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET ® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET ® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb ® ), oxygen content (SpOC™), carboxyhemoglobin (SpCO ® ), methemoglobin (SpMet ® ), and Pleth Variability Index (PVI ® ), in addition to SpO 2 , pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow ® Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow ® SET ® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine ® , a pioneer in the development of innovative brain function monitoring technology and devices. And in 2012, Masimo acquired the assets of Spire Semiconductor, LLC, a maker of advanced light emitting diode (LED) and other advanced component-level technologies; and PHASEIN AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. Masimo SET ® and Masimo rainbow ® SET ® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications ® ." Additional information about Masimo and its products may be found at www.masimo.com .

Forward-Looking Statements All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our financial condition, results of operations and business generally; expectations regarding our ability to design and deliver innovative new noninvasive technologies and reduce the cost of care; and demand for our technologies. These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: our dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors' assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the impact of the decline in the worldwide credit markets on us and our customers; the integration of acquisitions; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the "Risk Factors" section of our most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine are trademarks or registered trademarks of Masimo Corporation.

MASIMO CORPORATION  
CONDENSED CONSOLIDATED BALANCE SHEETS  
(unaudited) (in thousands)  
   
  June 29, 2013     December 29, 2012  
ASSETS          
Current assets          
  Cash and cash equivalents $ 78,073     $ 71,554  
  Accounts receivable, net of allowance for doubtful accounts   66,971       67,911  
  Royalties receivable   7,000       7,130  
  Inventories   55,717       47,358  
  Prepaid expenses   12,987       8,587  
  Deferred tax assets   12,001       12,911  
  Other current assets   3,251       3,896  
    Total current assets   236,000       219,347  
Deferred cost of goods sold   57,807       52,103  
Property and equipment, net   23,990       23,924  
Intangible assets, net   27,993       27,363  
Goodwill   22,469       22,824  
Deferred tax assets   21,497       22,363  
Other assets   7,473       8,022  
    Total assets $ 397,229     $ 375,946  
               
LIABILITIES AND EQUITY              
Current liabilities              
  Accounts payable $ 31,623     $ 27,033  
  Accrued compensation   24,020       25,021  
  Accrued liabilities   15,843       16,648  
  Income taxes payable   736       1,504  
  Deferred revenue   20,453       19,278  
  Current portion of capital lease obligations   114       55  
    Total current liabilities   92,789       89,539  
Deferred revenue   400       576  
Capital lease obligations, less current portion   226       60  
Other liabilities   10,328       10,103  
    Total liabilities   103,743       100,278  
               
Equity              
  Masimo Corporation stockholders' equity:              
    Common stock   56       57  
    Treasury stock   (83,454 )     (63,664 )
    Additional paid-in capital   266,000       258,783  
    Accumulated other comprehensive income   2,883       3,542  
    Retained earnings   107,827       74,361  
      Total Masimo Corporation stockholders' equity   293,312       273,079  
  Noncontrolling interest   174       2,589  
      Total equity   293,486       275,668  
      Total liabilities and equity $ 397,229     $ 375,946  
               
               
               
MASIMO CORPORATION  
CONDENSED CONSOLIDATED STATEMENTS OF INCOME  
(unaudited) (in thousands, except per share amounts)  
   
  Three Months Ended     Six Months Ended  
  June 29, 2013     June 30, 2012     June 29, 2013     June 30, 2012  
Revenue:                      
  Product $ 129,568     $ 115,317     $ 258,203     $ 227,536  
  Royalty   7,854       7,458       15,161       14,467  
Total revenue   137,422       122,775       273,364       242,003  
Cost of goods sold   46,190       41,343       92,551       81,266  
Gross profit   91,232       81,432       180,813       160,737  
Operating expenses:                              
  Selling, general and administrative   54,173       47,649       106,446       94,121  
  Research and development   13,879       11,110       28,046       21,615  
Total operating expenses   68,052       58,759       134,492       115,736  
Operating income   23,180       22,673       46,321       45,001  
Non-operating expense   (238 )     (462 )     (2,564 )     (1,044 )
Income before provision for income taxes   22,942       22,211       43,757       43,957  
Provision for income taxes   8,294       4,443       12,707       10,423  
Net income including noncontrolling interest   14,648       17,768       31,050       33,534  
Net (income) loss attributable to the noncontrolling interest   2,390       (71 )     2,416       (63 )
Net income attributable to Masimo Corporation stockholders $ 17,038     $ 17,697     $ 33,466     $ 33,471  
                               
Net income per share attributable to Masimo Corporation stockholders:                              
  Basic $ 0.30     $ 0.31     $ 0.59     $ 0.58  
  Diluted $ 0.30     $ 0.30     $ 0.58     $ 0.57  
Weighted average shares used in per share calculations:                              
  Basic   56,440       57,141       56,840       57,660  
  Diluted   57,204       58,084       57,607       58,612  
                               
                               
                               
MASIMO CORPORATION  
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  
(unaudited) (in thousands)  
   
  Six Months Ended  
  June 29, 2013     June 30, 2012  
Cash flows from operating activities:          
  Net income including noncontrolling interest $ 31,050     $ 33,534  
  Adjustments to reconcile net income including noncontrolling interest to net cash provided by operating activities:              
    Depreciation and amortization   5,600       3,973  
    Share-based compensation   6,390       7,837  
    Loss on disposal of property and equipment   78       --  
    Provision for (benefit from) doubtful accounts   314       (216 )
    Provision for obsolete inventory   556       533  
    Provision for warranty costs   1,280       1,222  
    Provision for (benefit from) deferred income taxes   1,687       (319 )
    Income tax benefit from exercise of stock options granted prior to January 1, 2006   436       138  
    Excess tax deficit from share-based compensation arrangements   504       285  
    Changes in operating assets and liabilities:              
      (Increase) decrease in accounts receivable   569       (7,154 )
      (Increase) decrease in royalties receivable   130       (151 )
      (Increase) decrease in inventories   (8,976 )     152  
      Increase in deferred cost of goods sold   (5,718 )     (367 )
      Increase in prepaid expenses   (4,475 )     (325 )
      (Increase) decrease in other assets   1,160       (1,896 )
      Increase (decrease) in accounts payable   4,644       (5,410 )
      Decrease in accrued compensation   (793 )     (1,166 )
      Increase (decrease) in accrued liabilities   (2,003 )     310  
      Decrease in income taxes payable   (1,261 )     (485 )
      Increase in deferred revenue   1,000       2,218  
      Increase (decrease) in other liabilities   231       (1,544 )
Net cash provided by operating activities   32,403       31,169  
               
Cash flows from investing activities:              
  Purchases of property and equipment   (3,936 )     (4,842 )
  Increase in intangible assets   (2,154 )     (1,220 )
  Cash paid for acquisition   --       (7,150 )
Net cash used in investing activities   (6,090 )     (13,212 )
               
Cash flows from financing activities:              
  Repayments of capital lease obligations   (96 )     (23 )
  Proceeds from issuance of common stock   897       593  
  Excess tax deficit from share-based compensation arrangements   (504 )     (285 )
  Repurchases of common stock   (19,790 )     (26,268 )
Net cash used in financing activities   (19,493 )     (25,983 )
Effect of foreign currency exchange rates on cash   (301 )     (339 )
Net increase (decrease) in cash and cash equivalents   6,519       (8,365 )
Cash and cash equivalents at beginning of period   71,554       129,882  
Cash and cash equivalents at end of period $ 78,073     $ 121,517  
               
               
               

Investor Contact: Eli Kammerman (949) 297-7077 ekammerman@masimo.com Media Contact: Mike Drummond (949) 297-7434 mdrummond@masimo.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 0

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 146

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 86

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 7

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 37

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 87

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Conrad Industries Reports Strong Third Quarter Financial Growth

Updated Category News Views 393

Conrad Industries Announces Third Quarter 2024 Financial Results Conrad Industries, Inc. (OTC Pink: CNRD) recently shared its financial performance for the third quarter ending September 30, 2024. The company reported a net income of $7.5 million, translating to earnings per diluted share of $1.49. This marks a significant turnaround from the third quarter of 2023, which...

Continue Reading
CytoSorbents Webinar Aims to Combat Sepsis and Septic Shock

Updated Category News Views 129

Understanding the Impact of Sepsis and Septic Shock Sepsis and septic shock pose serious threats in critical healthcare settings. Each year, millions of people are affected by these life-threatening conditions. Recognizing the need for innovative solutions, CytoSorbents Corporation has been at the forefront, utilizing its proprietary blood purification technologies to...

Continue Reading
Summa Defence Plc Updates Shareholding Structure Details

Updated Category News Views 271

Overview of Recent Notifications by Summa Defence Plc Summa Defence Plc has made important announcements relating to their shareholding structure and corporate governance, underscoring the dynamic nature of stockholder engagement. These events reflect the ongoing changes in ownership percentages that can significantly impact their operational strategy. Notification of...

Continue Reading
Quantifind's AI Tech Earns High Marks in Compliance

Updated Category News Views 17

Quantifind among the Industry's Top Innovators Well, here's a name to watch: Quantifind. Recognized as a Top 10 technology provider in financial crime and compliance, this Palo Alto-based firm is making waves. Our friends over at Chartis seem to think highly of them, and they don't toss out accolades willy-nilly. So, what's Quantifind doing that's so special? Pioneering...

Continue Reading
Dolby Laboratories Posts Strong Q1 Results with Promising Growth

Updated Category News Views 164

Strong Start for Dolby Laboratories in FY 2026 Dolby Laboratories, Inc. (NYSE: DLB) recently shared its financial results for the first quarter of fiscal 2026, showcasing promising developments despite the challenging market landscape. The company remains optimistic about its position and future growth opportunities. Kevin Yeaman, President and CEO of Dolby, expressed...

Continue Reading